Incidence, Prediction, and Prevention of Fractures After Kidney Transplantation: A Systematic Review Protocol.

IF 1.6 Q3 UROLOGY & NEPHROLOGY
Canadian Journal of Kidney Health and Disease Pub Date : 2024-12-23 eCollection Date: 2024-01-01 DOI:10.1177/20543581241306799
Andrea C Cowan, Karla Solo, Victoria Lebedeva, Yasaman Mohammadi Kamalabadi, Maha El-Shimy, Aayushi Joshi, Edith Ginika Olalike, Misa Tanaka, Adam G R Klotz, Hatoun Wahid Elazhary, Antonia Zhu, Adam Forster, Shafaz Veettil, Sachin G Nair, Maria Fernanda Servin Martinez, Dweeti Nayak, V Nikhila Priya, Catherine Wellan, Diana Maria Cespedes Arcani, Pavel S Roshanov
{"title":"Incidence, Prediction, and Prevention of Fractures After Kidney Transplantation: A Systematic Review Protocol.","authors":"Andrea C Cowan, Karla Solo, Victoria Lebedeva, Yasaman Mohammadi Kamalabadi, Maha El-Shimy, Aayushi Joshi, Edith Ginika Olalike, Misa Tanaka, Adam G R Klotz, Hatoun Wahid Elazhary, Antonia Zhu, Adam Forster, Shafaz Veettil, Sachin G Nair, Maria Fernanda Servin Martinez, Dweeti Nayak, V Nikhila Priya, Catherine Wellan, Diana Maria Cespedes Arcani, Pavel S Roshanov","doi":"10.1177/20543581241306799","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Kidney transplant recipients are uniquely exposed to the disordered bone metabolism associated with chronic kidney disease beginning before transplantation followed by chronic corticosteroid use after transplantation. Previous efforts to synthesize the rapidly accruing evidence regarding estimation and management of fracture risk in kidney transplant recipients are outdated and incomplete.</p><p><strong>Objective: </strong>To synthesize the evidence informing the overall incidence, patient-specific risk prediction, and methods of prevention of fractures in patient living with a kidney transplant.</p><p><strong>Design: </strong>Three systematic reviews will address the following questions: What is the overall incidence of skeletal fracture after kidney transplantation (review 1)? Which prediction models and individual prognostic factors predict fracture in kidney transplant recipients (review 2)? and How effective are different antifracture interventions at preventing fracture or improving surrogate markers of bone health in kidney transplant recipients (review 3)?</p><p><strong>Setting: </strong>Cohort studies (reviews 1 and 2) and randomized trials (review 2) with a mean/median follow-up ≥12 months beginning after transplant. Review 3: randomized trials or new-user cohort studies with concurrent controls evaluating the effect of antifracture interventions including bisphosphonates, calcium supplementation, cinacalcet, denosumab, parathyroid hormone analogues, parathyroidectomy, raloxifene, romosozumab, steroid withdrawal or minimization protocols after kidney transplant, vitamin D (both active and nutritional), other antifracture interventions.</p><p><strong>Patients: </strong>Adult kidney transplant recipients in studies published after the year 2000.</p><p><strong>Measurements: </strong>Review 1: incidence rate or cumulative risk of fracture. Review 2: For prediction models, measures of discrimination (eg, c-statistic), calibration (calibration curves, observed:expected ratios), and net benefit (ie, from decision curve analysis); for individual prognostic factors, relative measures of association with fractures. Review 3: measures of treatment effect on fractures and on surrogate markers of bone health (eg, bone mineral density, trabecular bone score).</p><p><strong>Methods: </strong>We searched MEDLINE, Embase, and the Cochrane Library using subject headings and keywords related to kidney transplant and fractures. Pairs of reviewers will screen records independently in duplicate to identify studies relevant to one or more of the 3 reviews and categorize each study accordingly. Single reviewers will extract data and evaluate risk of bias for each included study using one of the following tools as appropriate: the Quality of Prognostic Studies tool, the Prediction model Risk Of Bias ASsessment tool, the Risk Of Bias In Non-randomised Studies-of Interventions tool, and the Cochrane Risk of Bias 2.0 tool. A second reviewer will independently verify. We will synthesize study-level summary estimates by random-effects meta-analysis for review 1, by vote counting and random-effects meta-analysis in review 2, and by random effects pairwise and, if feasible, network meta-analysis in review 3. We will summarize findings according to latest guidance of the Grading of Recommendations Assessment, Development, and Evaluation Working Group applicable to each review.</p><p><strong>Limitations: </strong>Reliance on published studies is susceptible to publication bias, particularly in studies of prediction (review 2) and of treatment effects (review 3).</p><p><strong>Conclusions: </strong>This review will provide an evidence update on 3 topics of relevance to patients, clinicians, guideline developers, and researchers.</p>","PeriodicalId":9426,"journal":{"name":"Canadian Journal of Kidney Health and Disease","volume":"11 ","pages":"20543581241306799"},"PeriodicalIF":1.6000,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11672528/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Kidney Health and Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20543581241306799","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Kidney transplant recipients are uniquely exposed to the disordered bone metabolism associated with chronic kidney disease beginning before transplantation followed by chronic corticosteroid use after transplantation. Previous efforts to synthesize the rapidly accruing evidence regarding estimation and management of fracture risk in kidney transplant recipients are outdated and incomplete.

Objective: To synthesize the evidence informing the overall incidence, patient-specific risk prediction, and methods of prevention of fractures in patient living with a kidney transplant.

Design: Three systematic reviews will address the following questions: What is the overall incidence of skeletal fracture after kidney transplantation (review 1)? Which prediction models and individual prognostic factors predict fracture in kidney transplant recipients (review 2)? and How effective are different antifracture interventions at preventing fracture or improving surrogate markers of bone health in kidney transplant recipients (review 3)?

Setting: Cohort studies (reviews 1 and 2) and randomized trials (review 2) with a mean/median follow-up ≥12 months beginning after transplant. Review 3: randomized trials or new-user cohort studies with concurrent controls evaluating the effect of antifracture interventions including bisphosphonates, calcium supplementation, cinacalcet, denosumab, parathyroid hormone analogues, parathyroidectomy, raloxifene, romosozumab, steroid withdrawal or minimization protocols after kidney transplant, vitamin D (both active and nutritional), other antifracture interventions.

Patients: Adult kidney transplant recipients in studies published after the year 2000.

Measurements: Review 1: incidence rate or cumulative risk of fracture. Review 2: For prediction models, measures of discrimination (eg, c-statistic), calibration (calibration curves, observed:expected ratios), and net benefit (ie, from decision curve analysis); for individual prognostic factors, relative measures of association with fractures. Review 3: measures of treatment effect on fractures and on surrogate markers of bone health (eg, bone mineral density, trabecular bone score).

Methods: We searched MEDLINE, Embase, and the Cochrane Library using subject headings and keywords related to kidney transplant and fractures. Pairs of reviewers will screen records independently in duplicate to identify studies relevant to one or more of the 3 reviews and categorize each study accordingly. Single reviewers will extract data and evaluate risk of bias for each included study using one of the following tools as appropriate: the Quality of Prognostic Studies tool, the Prediction model Risk Of Bias ASsessment tool, the Risk Of Bias In Non-randomised Studies-of Interventions tool, and the Cochrane Risk of Bias 2.0 tool. A second reviewer will independently verify. We will synthesize study-level summary estimates by random-effects meta-analysis for review 1, by vote counting and random-effects meta-analysis in review 2, and by random effects pairwise and, if feasible, network meta-analysis in review 3. We will summarize findings according to latest guidance of the Grading of Recommendations Assessment, Development, and Evaluation Working Group applicable to each review.

Limitations: Reliance on published studies is susceptible to publication bias, particularly in studies of prediction (review 2) and of treatment effects (review 3).

Conclusions: This review will provide an evidence update on 3 topics of relevance to patients, clinicians, guideline developers, and researchers.

背景:肾移植受者在移植前就患有慢性肾脏病,移植后又长期使用皮质类固醇,因此骨代谢紊乱。以往对肾移植受者骨折风险评估和管理方面快速积累的证据进行综合的工作既过时又不完整:综合有关肾移植患者骨折的总体发生率、患者特异性风险预测和预防方法的证据:设计:三篇系统综述将探讨以下问题:肾移植后骨骼骨折的总体发生率是多少(综述 1)?哪些预测模型和个体预后因素可预测肾移植受者的骨折(综述 2)?不同的抗骨折干预措施在预防肾移植受者骨折或改善骨骼健康代用指标方面的效果如何(综述 3)?队列研究(综述 1 和 2)和随机试验(综述 2),平均/中位随访时间≥12 个月。综述3:评估抗骨折干预措施效果的随机试验或新用户队列研究,同时进行对照,包括双膦酸盐、钙补充剂、西那卡西特、地诺索单抗、甲状旁腺激素类似物、甲状旁腺切除术、雷洛昔芬、罗莫索单抗、肾移植后类固醇停用或最小化方案、维生素D(活性和营养)、其他抗骨折干预措施:患者:2000 年后发表的研究中的成年肾移植受者:回顾 1:骨折发生率或累积风险。综述 2:对于预测模型,判别度(如 c 统计量)、校准(校准曲线、观察到的与预期的比率)和净效益(即决策曲线分析);对于单个预后因素,与骨折相关性的相对测量。综述 3:治疗对骨折和骨骼健康代用指标(如骨矿物质密度、骨小梁评分)的影响测量:我们使用与肾移植和骨折相关的主题词和关键词检索了 MEDLINE、Embase 和 Cochrane 图书馆。一对审稿人将独立筛选记录,一式两份,以确定与 3 篇综述中的一篇或多篇相关的研究,并对每篇研究进行相应分类。单个审稿人将酌情使用以下工具之一提取数据并评估每项纳入研究的偏倚风险:预后研究质量工具、预测模型偏倚风险评估工具、非随机干预研究中的偏倚风险工具以及 Cochrane 偏倚风险 2.0 工具。第二位审稿人将进行独立核实。在综述 1 中,我们将通过随机效应荟萃分析来综合研究水平的汇总估计值;在综述 2 中,我们将通过计票和随机效应荟萃分析来综合研究水平的汇总估计值;在综述 3 中,我们将通过随机效应配对分析和网络荟萃分析(如果可行)来综合研究水平的汇总估计值:局限性:依赖已发表的研究容易出现发表偏差,尤其是预测研究(综述 2)和治疗效果研究(综述 3):本综述将提供与患者、临床医生、指南制定者和研究人员相关的 3 个主题的最新证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.00
自引率
5.90%
发文量
84
审稿时长
12 weeks
期刊介绍: Canadian Journal of Kidney Health and Disease, the official journal of the Canadian Society of Nephrology, is an open access, peer-reviewed online journal that encourages high quality submissions focused on clinical, translational and health services delivery research in the field of chronic kidney disease, dialysis, kidney transplantation and organ donation. Our mandate is to promote and advocate for kidney health as it impacts national and international communities. Basic science, translational studies and clinical studies will be peer reviewed and processed by an Editorial Board comprised of geographically diverse Canadian and international nephrologists, internists and allied health professionals; this Editorial Board is mandated to ensure highest quality publications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信